CL2014001155A1 - Method for reducing the uric acid in the serum of a subject with hyperuricemia, administering a first urate reducing agent and a second urate reducing agent; pharmaceutical composition; pharmaceutical kit; use in the treatment of acute, chronic, moderate, refractory or severe gout. - Google Patents

Method for reducing the uric acid in the serum of a subject with hyperuricemia, administering a first urate reducing agent and a second urate reducing agent; pharmaceutical composition; pharmaceutical kit; use in the treatment of acute, chronic, moderate, refractory or severe gout.

Info

Publication number
CL2014001155A1
CL2014001155A1 CL2014001155A CL2014001155A CL2014001155A1 CL 2014001155 A1 CL2014001155 A1 CL 2014001155A1 CL 2014001155 A CL2014001155 A CL 2014001155A CL 2014001155 A CL2014001155 A CL 2014001155A CL 2014001155 A1 CL2014001155 A1 CL 2014001155A1
Authority
CL
Chile
Prior art keywords
reducing agent
urate
hyperuricemia
refractory
moderate
Prior art date
Application number
CL2014001155A
Other languages
Spanish (es)
Inventor
Brian K Roberts
Gopal Chandra Saha
Brian Edward Lavan
Charles A Mcwherther
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of CL2014001155A1 publication Critical patent/CL2014001155A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2014001155A 2011-11-04 2014-05-02 Method for reducing the uric acid in the serum of a subject with hyperuricemia, administering a first urate reducing agent and a second urate reducing agent; pharmaceutical composition; pharmaceutical kit; use in the treatment of acute, chronic, moderate, refractory or severe gout. CL2014001155A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059394 WO2013066349A1 (en) 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Publications (1)

Publication Number Publication Date
CL2014001155A1 true CL2014001155A1 (en) 2015-01-16

Family

ID=48192533

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001155A CL2014001155A1 (en) 2011-11-04 2014-05-02 Method for reducing the uric acid in the serum of a subject with hyperuricemia, administering a first urate reducing agent and a second urate reducing agent; pharmaceutical composition; pharmaceutical kit; use in the treatment of acute, chronic, moderate, refractory or severe gout.

Country Status (13)

Country Link
EP (1) EP2773336A4 (en)
JP (1) JP6202633B2 (en)
KR (1) KR20140121383A (en)
CN (2) CN109908124A (en)
AU (1) AU2011380507B2 (en)
CA (1) CA2859686C (en)
CL (1) CL2014001155A1 (en)
IL (1) IL232386A0 (en)
MX (1) MX357507B (en)
NZ (1) NZ624708A (en)
SG (1) SG11201402032RA (en)
WO (1) WO2013066349A1 (en)
ZA (1) ZA201403575B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836209A4 (en) * 2012-04-13 2015-11-25 Cymabay Therapeutics Inc Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP6368756B2 (en) * 2016-10-20 2018-08-01 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Method of treating hyperuricemia in patients suffering from gout using halofenate or halofenic acid and a second uric acid lowering drug
CN108014108A (en) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 The application of lesinurad or its pharmaceutically acceptable salt in the medicine for treating or preventing Cushing syndrome is prepared
US11446317B2 (en) 2017-10-26 2022-09-20 Otsuka Pharmaceutical Co., Ltd. Inositol phosphate-containing composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
WO2011032175A1 (en) * 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto

Also Published As

Publication number Publication date
ZA201403575B (en) 2015-11-25
EP2773336A4 (en) 2015-06-03
CN104066427A (en) 2014-09-24
EP2773336A1 (en) 2014-09-10
MX2014005400A (en) 2015-02-12
CA2859686C (en) 2018-09-11
JP6202633B2 (en) 2017-09-27
JP2014532758A (en) 2014-12-08
MX357507B (en) 2018-07-12
NZ624708A (en) 2015-11-27
KR20140121383A (en) 2014-10-15
AU2011380507B2 (en) 2017-06-15
CA2859686A1 (en) 2013-05-10
IL232386A0 (en) 2014-06-30
SG11201402032RA (en) 2014-09-26
CN109908124A (en) 2019-06-21
WO2013066349A1 (en) 2013-05-10
AU2011380507A1 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
CL2012003548A1 (en) Pharmaceutical modified-release composition comprising spheres of immediate release and spheres of delayed release of 2- [3-cyano-4- (2-methylpropoxy) phenyl] -4-methylthiazol-5-carboxylic acid (febuxostat), selective xanthine inhibitor oxidoreductase; dosage form; and method of treatment for gout, among others.
CL2013001602A1 (en) Method to reduce or inhibit the progression of the level of fatigue in patients with multiple sclerosis and to provide them with neuroprotection comprising orally administering laquinimod or a salt thereof; laquinimod to reduce the level of fatigue, improve functional status and deliver neuroprotection in multiple sclerosis.
BR112013022332A2 (en) methods for treating and / or preventing hyperuricemia or a metabolic disorder associated with hyperuricemia, and for improving the control of blood uric acid level; and, pharmaceutical composition.
BR112015003397A2 (en) compound, pharmaceutical composition, use of the compound and method for treating a rorgammat-mediated disease or condition in a patient.
BR112014010177A2 (en) compound, pharmaceutical composition, use of the compound, and method for the prophylaxis or treatment of a disease state or condition
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
BR112015003332A2 (en) compound, pharmaceutical composition, use of the compound and method for treating a rorgammat-mediated disease or condition in a patient
BR112014010206A2 (en) compound, pharmaceutical composition, use of compound, and method for the prophylaxis or treatment of a disease state or condition
BR112015003398A2 (en) compound, pharmaceutical composition, use of the compound and method for treating a rorgammat-mediated disease or condition in a patient
WO2012129084A3 (en) Glucosylceramide synthase inhibitors
EA201400119A1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND THEIR APPLICATION
CL2013001136A1 (en) A phosphodiesterase 7 (pde7) inhibitory agent to be used in the treatment or reduction of the possibility of an addiction; and pharmaceutical composition, unit dosage form and pharmaceutical kit including phosphodiesterase 7 inhibitor (pde7) and an additional therapeutic agent.
BR112014010179A2 (en) compound, pharmaceutical composition, use of a compound, and method for the prophylaxis or treatment of a condition or condition
CL2014000849A1 (en) Compounds derived from substituted benzylindazoles, bub1 kinase inhibitors; manufacturing procedure; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of hyperproliferative diseases.
BRPI0816097A2 (en) pharmaceutical composition, method for treating erythema in a patient with rosacea, and, use of a composition.
CL2014001155A1 (en) Method for reducing the uric acid in the serum of a subject with hyperuricemia, administering a first urate reducing agent and a second urate reducing agent; pharmaceutical composition; pharmaceutical kit; use in the treatment of acute, chronic, moderate, refractory or severe gout.
CL2013000513A1 (en) Use of a pharmaceutical composition comprising: a) a monohydrated compound consisting of two anions and an ob) valsartan cation and an ethyl acid ester, for the treatment of hypertension and / or the prevention or treatment of heart failure in a mammal that receives anti-coagulant therapy.
CL2014000267A1 (en) Liquid pharmaceutical formulation comprising ketoprofen, amitriptyline and oxymetazoline; pharmaceutical kit; method to prevent or treat inflammation.
CL2013002905A1 (en) Pharmaceutical composition comprising fimasartan, a salt, solvate or hydrate thereof and amlodipine, an isomer, salt, solvate or hydrate thereof; Use in the treatment of hypertension and cardiovascular diseases.
CL2013001564A1 (en) Method to treat overweight or obesity that includes administering naltrexone and bupropion; method to increase the bioavailability of naltrexone and bupropion in a combination therapy; use of naltrexone and bupropion to treat overweight or obesity and increase the bioavailability of these drugs; pharmaceutical composition
CL2013003700A1 (en) Topical ophthalmological pharmaceutical composition comprising regorafenib, which is suspended in a pharmaceutically acceptable vehicle; manufacturing procedure and its use to treat or prevent an ophthalmological disorder.
CL2015000857A1 (en) A pharmaceutical composition consisting of a first layer comprising metformin and a second layer comprising gemigliptin; its method of preparation, useful for the prevention and treatment of diabetes.
CL2014001157A1 (en) Method for treating a gout attack comprising administering a compound of formula (i) and a second urate reducing agent.
GB201014391D0 (en) Drug composition and its use in therapy
CL2013002006A1 (en) Pharmaceutical composition comprising an isolated antibody that specifically binds to the stem cell factor; antibody production method; and its use to treat or prevent a disease of tissue or fibrotic remodeling in a subject.